The short answer
Gabapentin is FDA-approved for nerve pain after shingles and certain seizures, not for hot flashes. Using it for hot flashes is off-label, but the Menopause Society's 2023 statement recommends it based on good evidence, especially for night-time symptoms. Oxybutynin is also recommended with more limited evidence and anticholinergic concerns. Clonidine is not recommended.
Off-label does not mean FDA approved
None of these three medicines is FDA approved to treat hot flashes. A prescriber may use them off-label when evidence and individual circumstances support it.
Gabapentin can cause dizziness and sleepiness, and the FDA has warned about serious breathing problems when it is combined with opioids or other central nervous system depressants, or used by people with lung disease or older adults. Antiepileptic drugs carry a warning about suicidal thoughts. It should not be stopped abruptly without guidance.
Current label check
The medication-specific claims on this page were checked against these current product labels on 2026-10-03. All three uses on this page are off-label; claims about hot flashes rest on The Menopause Society 2023 statement, not on these labels.
| Product label | Label date | Boxed warning on that label |
|---|---|---|
| Neurontin (gabapentin) | 2026-05-12 | None; hot flashes are not a labeled use |
| Catapres-TTS (clonidine) patch | 2026-01-06 | None; labeled for hypertension only |
Established evidence
Gabapentin: the best-supported off-label option
Randomized trials have shown gabapentin reduces hot flash frequency and severity more than placebo. Because drowsiness is a common side effect, it is often discussed for people whose night sweats disrupt sleep, with dosing at bedtime decided by the prescriber.
It is not a hormone, so it is considered by people who cannot or prefer not to use estrogen, including some breast cancer survivors.
Established evidence
Gabapentin side effects and interactions
- Dizziness, drowsiness, and unsteadiness
- Swelling of the legs and weight gain
- Additive sedation and breathing risk with opioids, alcohol, or other sedatives
- Dose adjustment needed for reduced kidney function
- Misuse potential in some people
Limited human evidence
Oxybutynin: recommended, with caution
Oxybutynin is approved for overactive bladder. Trials found it reduces hot flashes, and the Menopause Society rates the evidence Level I to II. It is anticholinergic, which causes dry mouth, constipation, and blurred vision, and long-term anticholinergic use has been associated with cognitive decline and dementia risk in older adults. That is a meaningful consideration for midlife and older patients.
Not established
Clonidine: not recommended
Clonidine, a blood pressure medicine, showed only small benefits in older studies and commonly causes drowsiness, dry mouth, constipation, and low blood pressure, with rebound high blood pressure if stopped suddenly. The 2023 Menopause Society statement does not recommend it for hot flashes.
How nonhormonal options compare
The ratings below come from the 2023 Menopause Society nonhormone statement. Hormone therapy remains the most effective treatment for appropriate candidates.
| Option | FDA approved for hot flashes? | 2023 recommendation |
|---|---|---|
| Fezolinetant (Veozah) | Yes | Recommended, Level I |
| Elinzanetant (Lynkuet) | Yes (approved after the 2023 statement) | Not yet rated in the 2023 statement |
| Paroxetine 7.5 mg (Brisdelle) | Yes | SSRIs/SNRIs recommended, Level I |
| Other SSRIs/SNRIs | No (off-label) | Recommended, Level I |
| Gabapentin | No (off-label) | Recommended, Level I |
| Oxybutynin | No (off-label) | Recommended, Levels I to II |
| Clonidine | No (off-label) | Not recommended |
| Pregabalin | No | Not recommended |
Questions to ask a healthcare professional
- Why an off-label option rather than an FDA-approved one for me?
- Will this interact with my pain, sleep, or mood medicines?
- How should I stop it if it does not help?
Questions, answered
What people ask about Neurontin
Is gabapentin FDA approved for hot flashes?+
No. It is approved for postherpetic neuralgia and as add-on therapy for partial seizures. Use for hot flashes is off-label, though supported by Menopause Society guidance.
Does gabapentin help night sweats?+
Trials show it reduces hot flashes, and its sedating effect is one reason clinicians consider bedtime use for night sweats that disrupt sleep.
Is clonidine still used for hot flashes?+
Some clinicians used it historically, but the 2023 Menopause Society statement does not recommend it because of limited benefit and side effects.
Does Kindr Health offer gabapentin?+
This page is educational and does not state or imply availability through Kindr Health.
Kindr Health does not claim to offer Neurontin on this page. Availability and prescribing are not implied.
A broader care pathway
Explore menopause care
Learn how Kindr Health care pathways work. An educational page is not a statement that this medication is available or appropriate for you.
SOURCES & REFERENCES
Every clinical claim on this page is sourced.
- The 2023 nonhormone therapy position statement of The North American Menopause Society (2023) — The Menopause Society (Menopause journal). menopause.org/wp-content/uploads/professional/2023-nonhormone-therapy-position-statement.pdf
- Gabapentin prescribing information (current label) (2026) — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Gabapentin
- FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin and pregabalin (2019) — U.S. Food and Drug Administration. www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin
This resource is educational and does not replace individualized medical advice. Do not start, stop, or change a prescription without guidance from a licensed healthcare professional.